Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Obsidian Therapeutics has raised $160.5M in total funding. The most recent round was Series C. The last funding was announced in April 2024.
Obsidian Therapeutics's investors include RA Capital Management, Wellington Management, Janus Henderson Investors, Vertex Ventures, Samsara BioCapital.
Obsidian Therapeutics is headquartered in Cambridge, United States.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Obsidian Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Obsidian Therapeutics — Funding & Investors." VCBacked, April 3, 2024, https://www.vcbacked.co/company/obsidian-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Obsidian Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/obsidian-therapeutics
{{cite web |title=Obsidian Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/obsidian-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated